The study of matched pre/on-treatment biopsies of melanoma patients having received an anti-PD-1 revealed a decrease in frequency of effector memory CD4 + T cells post-treatment, whilst an on-treatment increase in intratumoral CD4 + effector T cells was found to be a negative correlate of response [97]. This evidence concerns the gene PDCD1 and melanoma.